HIF prolyl hydroxylase inhibitor
Vadadustat
Brand names: Vafseo
Adult dose
Dose: Initial 300mg PO OD; titrate to Hb (max 600mg/day)
Route: PO
Frequency: OD
Clinical pearls
- Anaemia of CKD on dialysis (alternative to ESAs)
- Specialist renal
Contraindications
- Hepatic impairment (severe)
- Recent thromboembolism
- Pregnancy
- Hypersensitivity
Side effects
- Hypertension
- Thromboembolism
- Diarrhoea
- Hepatotoxicity
- Hyperkalaemia
Interactions
- Bile acid sequestrants (separate by 6h)
- BCRP substrates
- UGT1A1 substrates
Monitoring
- Hb
- BP
- LFTs
- K+
Reference: BNF; NICE; SmPC; https://bnf.nice.org.uk/drugs/vadadustat/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia